arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PERRIGO Co plc

PRGO
$13.84 ▼ -0.47 (-3.28%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
55 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PERRIGO Co plc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.9B
Dividend Yield 2.10%
Revenue Growth -3.2%
Op. Margin 2.3%
ROIC 0.3%
FCF / Share $0.49
Trailing P/E 25.6x
Price / Book 0.8x
FCF Yield 3.6%
Debt / Equity 1.31
info Valuation on last close. End-of-day price, Sep 23, 2026.

55-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.02B
↓ -3.2%
Net Income Profit after all expenses
$-398.60M
↓ -6128.1%
Operating Margin Operating profit as % of sales
2.3%
↑ +106.0% 8th
FCF / Share Free cash flow per share
$0.49
↑ +153.5%
Long-Term Debt Long-term obligations
$3.28B
↓ -9.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
18
Returns
17
Financial Health
29
Cash Quality
19

Dividend History

Dividend / share · sourced from SEC filings
$1.16 Latest / share
+5.5% YoY
+11.5% 11-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 55 quarters